Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SHR-1701 Combined With Rivoceranib, With or Without SHR-2554, in Patients With Advanced Gastric Cancer Who Have Failed First-Line Immunotherapy

NCT07311408 is registered in ClinicalTrials.gov with Jingdong Zhang as lead sponsor.

NCT NCT07311408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07311408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SHR-1701 Combined With Rivoceranib, With or Without SHR-2554, in Patients With Advanced Gastric Cancer Who Have Failed First-Line Immunotherapy
Lead sponsor
Jingdong Zhang
Phase
Phase 2
Overall status
Recruiting
Start date
January 1, 2026
Completion date
December 1, 2029
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer (gc), gastroesophageal junction adenocarcinoma